BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 1904164)

  • 1. [Anti-retroviral therapy of HIV-infection. With preliminary results of the Swiss postmarketing surveillance of zidovudine].
    Jost J; Lüthy R
    Schweiz Med Wochenschr; 1991 Apr; 121(16):555-65. PubMed ID: 1904164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Once versus twice daily administration of didanosine in children with symptomatic HIV-associated disease who were intolerant to or clinically deteriorated on zidovudine. The Italian Pediatric Collaborative Study Group on Didanosine.
    Marchisio P; Principi N; Gabiano C; Galli L; Gattinara GC; Caselli D; Zuccotti G; La Regina A; Paga C
    Antivir Ther; 1997 Jan; 2(1):47-55. PubMed ID: 11322266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of zidovudine compared with didanosine on health status and functioning in persons with advanced HIV infection and a varying duration of prior zidovudine therapy. AIDS Clinical Trials Group 116/117 Study Group.
    Bozzette SA; Kanouse DE; Duan N; Berry S; Richman DD
    Antivir Ther; 1996 Jan; 1(1):21-32. PubMed ID: 11322256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zidovudine (Retrovir) update.
    Rachlis AR
    CMAJ; 1990 Dec; 143(11):1177-85. PubMed ID: 2224694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [HIV infection--current possibilities in antiviral therapy].
    Hirschel B
    Ther Umsch; 1994 Aug; 51(8):545-50. PubMed ID: 7940411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies of zidovudine in combination with didanosine and zalcitabine.
    Jablonowski H
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S52-6. PubMed ID: 8595509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current perspectives on antiretroviral therapy.
    Fletcher CV
    Pharmacotherapy; 1993; 13(6):627-33. PubMed ID: 7508101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Results of zidovudine treatment of 9 vertically HIV infected children].
    Berkefeld I; Fuchs A; Wahn V
    Monatsschr Kinderheilkd; 1993 Jun; 141(6):498-504. PubMed ID: 8101636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antiretroviral therapy in Switzerland 1991].
    Hirschel B; Vanhems P
    Schweiz Med Wochenschr; 1991 Aug; 121(34):1187-93. PubMed ID: 1925447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Report on a 3-year follow-up zidovudine (AZT) treatment in a group of HIV-positive patients with congenital clotting disorders.
    Sartori MT; Mares M; Zerbinati P; Stocco D; Girolami A
    Haematologia (Budap); 1994; 26(1):17-27. PubMed ID: 7959371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Tuberculosis in compromised hosts].
    Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.
    Elion R; Kaul S; Knupp C; Adler M; Cross AP; Dunkle LM; Kelleher T
    Clin Ther; 1999 Nov; 21(11):1853-63. PubMed ID: 10890257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Zidovudine therapy in 141 patients with symptoms of HIV infection; a multicenter study].
    Perenboom R; Reiss P; Danner SA; van 't Wout JW
    Ned Tijdschr Geneeskd; 1990 Jan; 134(3):120-4. PubMed ID: 2405287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxyurea and didanosine is a more potent combination than hydroxyurea and zidovudine.
    Foli A; Lori F; Maserati R; Tinelli C; Minoli L; Lisziewicz J
    Antivir Ther; 1997 Jan; 2(1):31-8. PubMed ID: 11322264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection.
    Vella S; Lazzarin A; Carosi G; Sinicco A; Armignacco O; Angarano G; Andreoni M; Tambussi G; Chiodera A; Floridia M; Scaccabarozzi S; Facey K; Duncan I; Boudes P; Bragman K
    Antivir Ther; 1996 Aug; 1(3):129-40. PubMed ID: 11322246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.